Exploration of mechanism of drug resisitance in cancer acidic condition and development of novel therapeutic drug
Project/Area Number |
26830108
|
Research Category |
Grant-in-Aid for Young Scientists (B)
|
Allocation Type | Multi-year Fund |
Research Field |
Tumor therapeutics
|
Research Institution | The University of Tokushima |
Principal Investigator |
|
Project Period (FY) |
2014-04-01 – 2016-03-31
|
Project Status |
Completed (Fiscal Year 2015)
|
Budget Amount *help |
¥3,900,000 (Direct Cost: ¥3,000,000、Indirect Cost: ¥900,000)
Fiscal Year 2015: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
Fiscal Year 2014: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
Keywords | がん酸性環境 / pim2 / 酸性環境 / 多発性骨髄腫 / cucurbitacin |
Outline of Final Research Achievements |
Tumor acidity has been known to confer drug resistance in cancers, however, therapeutic drug targetting tumor acidic microenvironment have not been developed. Pim2 was highly upregulated in myeloma cells, and SIRT1, BCRP, monocarbonic transporter were upregulated in acidic condition. Pim inhibitor improved all of these change. We explored compound library in faculty of pharmaceutical sciences,and found cucurbitacinB was one of a candidates of therapeutic drugs for targeting tumor acidic condition.
|
Report
(3 results)
Research Products
(16 results)
-
[Journal Article] Susceptibility to bendamustine considerably varies among myeloma cells, but is enhanced in acidic conditions2016
Author(s)
Shingen NAKAMURA , Hirokazu MIKI , Asuka ODA , Ryota AMACHI , Jumpei TERAMACHI , Kimiko SOGABE , Hikaru FUJINO , Tomoko MARUHASHI , Shiro FUJII , Kumiko KAGAWA and Masahiro ABE
-
Journal Title
International Journal of Myeloma
Volume: 6
Pages: 7-11
Related Report
Peer Reviewed / Open Access / Acknowledgement Compliant
-
-
[Journal Article] Effective impairment of myeloma cells and their progenitors by blockade of monocarboxylate transportation.2015
Author(s)
Hanson DJ, Nakamura S, Amachi R, Hiasa M, Oda A1, Tsuji D, Itoh K, Harada T, Horikawa K, Teramachi J, Miki H, Matsumoto T, Abe M.
-
Journal Title
oncotarget
Volume: 6
Pages: 33568-33586
Related Report
Peer Reviewed / Open Access / Acknowledgement Compliant
-
-
[Journal Article] Lipopolysaccharide-Induced CXCL10 mRNA Level and Six Stimulant-mRNA Combinations in Whole Blood: Novel Biomarkers for Bortezomib Responses Obtained from a Prospective Multicenter Trial for Patients with Multiple Myeloma.2015
Author(s)
Watanabe T, Mitsuhashi M, Sagawa M, Ri M, Suzuki K, Abe M, Ohmachi K, Nakagawa Y, Nakamura S, Chosa M, Iida S, Kizaki M.
-
Journal Title
NAID
Related Report
Peer Reviewed / Open Access
-
[Journal Article] Pim-2 kinase is an important target of treatment for tumor progression and bone loss in myeloma.2015
Author(s)
Hiasa M, Teramachi J, Oda A, Amachi R, Harada T, Nakamura S, Miki H, Fujii S, Kagawa K, Watanabe K, Endo I, Kuroda Y, Yoneda T, Tsuji D, Nakao M, Tanaka E, Hamada K, Sano S, Itoh K, Matsumoto T, Abe M
-
Journal Title
Leukemia
Volume: 29
Pages: 207-217
Related Report
Peer Reviewed / Open Access / Acknowledgement Compliant
-
[Journal Article] Induction of endoplasmic reticulum stress by bortezomib sensitizes myeloma cells to DR5-mediated cell death2015
Author(s)
Miki H, Nakamura S, Oda A, Amachi R, Watanabe K, Hanson D, Teramachi J, Hiasa M, Yagi H, Sogabe K, Takahashi M, Maruhashi T, Udaka K, Harada T, Fujii S, Nakano A, Kagawa K, Ri M, Iida S, Ozaki S, Matsumoto T, Abe M.
-
Journal Title
International Journal of Myeloma
Volume: 5
Pages: 1-7
Related Report
Peer Reviewed / Open Access / Acknowledgement Compliant
-
[Presentation] Cytotoxic efficacy of Pim inhibitors and anti-myeloma agents in combination2015
Author(s)
Shingen Nakamura, Hirokazu Miki, Hirofumi Tenshin, Ryota Amachi, Derek Hanson, Keiichiro Watanabe, Jumpei Teramachi, Asuka Oda, Kimiko Sogabe, Hikaru Fujino, Tomoko Maruhashi, Shiro Fujii ,Kumiko Kagawa, Masahiro Abe
Organizer
日本血液学会
Place of Presentation
石川県立音楽堂、ANAクラウンプラザホテル金沢、 ホテル日航金沢、ホテル金沢、ほか (石川県金沢市)
Year and Date
2015-10-16
Related Report
-
[Presentation] Alteration of Pim-2 expression by clinically available anti-myeloma agents: combinatory anti-myeloma effects with Pim inhibition2015
Author(s)
Shingen Nakamura, Hirokazu Miki, Hirofumi Tenshin, Ryota Amachi, Derek Hanson, Keiichiro Watanabe, Jumpei Teramachi Asuka Oda, Kimiko Sogabe, Hikaru Fujino, Tomoko Maruhashi, Shiro Fujii ,Kumiko Kagawa, Masahiro Abe
Organizer
international myeloma workshop
Place of Presentation
Rome(Italy)
Year and Date
2015-09-23
Related Report
Int'l Joint Research
-
[Presentation] Combinatory effects of Pim inhibitor with clinically available anti-myeloma agents2015
Author(s)
Shingen Nakamura, Hirokazu Miki, Hirofumi Tenshin, Ryota Amachi, Derek Hanson, Keiichiro Watanabe, Jumpei Teramachi, Asuka Oda, Kimiko Sogabe, Hikaru Fujino, Tomoko Maruhashi, Shiro Fujii ,Kumiko Kagawa, Masahiro Abe
Organizer
日本骨髄腫学会
Place of Presentation
くまもと森都心プラザ (熊本県熊本市)
Year and Date
2015-05-17
Related Report
-
[Presentation] Cytotoxic efficacy of Pim inhibitors and anti-myeloma agents in combination2015
Author(s)
Shingen Nakamura, Hirokazu Miki, Hirofumi Tenshin, Ryota Amachi, Derek Hanson, Keiichiro Watanabe, Jumpei Teramachi, Asuka Oda, Kimiko Sogabe, Hikaru Fujino, Tomoko Maruhashi, Shiro Fujii ,Kumiko Kagawa, Masahiro Abe
Organizer
日本骨髄腫学会
Place of Presentation
くまもと森都心プラザ(熊本県熊本市)
Year and Date
2015-05-17
Related Report
-
-
-
-
-